Contribute Try STAT+ Today

More than 10 years after its discovery, a special type of stem cell is being put to the test.

In 2014 scientists in Japan launched the world’s first clinical trials using the cells, called induced pluripotent stem cells, and now scientists in the United States are in the run-up to this country’s first trial. iPS cells, as they are known, start as another type of cell — often blood or skin — before scientists coax them back into becoming stem cells. From there, researchers can then steer them to differentiate into another type of cell, building a vast wave of hope for the cells’ therapeutic potential.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.